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Although mutation of APC or CTNNB1 (b-catenin) is rare in breast cancer, activation of Wnt signalling is nonetheless thought to play
an important role in breast tumorigenesis, and epigenetic silencing of Wnt antagonist genes, including the secreted frizzled-related
protein (SFRP) and Dickkopf (DKK) families, has been observed in various tumours. In breast cancer, frequent methylation and
silencing of SFRP1 was recently documented; however, altered expression of other Wnt antagonist genes is largely unknown. In the
present study, we found frequent methylation of SFRP family genes in breast cancer cell lines (SFRP1, 7 out of 11, 64%; SFRP2, 11 out
of 11, 100%; SFRP5, 10 out of 11, 91%) and primary breast tumours (SFRP1, 31 out of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5,5 5
out of 78, 71%). We also observed methylation of DKK1, although less frequently, in cell lines (3 out of 11, 27%) and primary tumours
(15 out of 78, 19%). Breast cancer cell lines express various Wnt ligands, and overexpression of SFRPs inhibited cancer cell growth. In
addition, overexpression of a b-catenin mutant and depletion of SFRP1 using small interfering RNA synergistically upregulated
transcriptional activity of T-cell factor/lymphocyte enhancer factor. Our results confirm the frequent methylation and silencing of Wnt
antagonist genes in breast cancer, and suggest that their loss of function contributes to activation of Wnt signalling in breast
carcinogenesis.
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Wnt ligands are secreted proteins that bind to transmembrane
receptors in the Frizzled (Fz) family. During normal develop-
mental processes, the resultant Wnt signalling plays essential roles
in the regulation of cell proliferation, patterning and fate
determination (Cadigan and Nusse, 1997). The binding of Wnt
to Fz leads to dephosphorylation and stabilisation of b-catenin,
enabling it to be translocated into the nucleus, where it interacts
with members of the T-cell factor/lymphocyte enhancer factor
(TCF/LEF) family of transcription factors to stimulate the
expression of target genes. This signalling pathway is strongly
implicated in tumorigenesis; indeed, the first mammalian Wnt
isoform was identified based on its ability to promote mouse
mammary tumorigenesis (Polakis, 2000). In addition, aberrant
nuclear and cytoplasmic localisation of b-catenin is frequently
observed in human breast cancer (Lin et al, 2000; Ryo et al, 2001;
Chung et al, 2004). In contrast to colorectal cancer (CRC),
however, mutation of APC, AXIN or CTNNB1 (b-catenin) is rare in
breast cancer, indicating that other mechanisms are responsible
for the activation of b-catenin. These mechanisms could include
increased expression of Wnt ligand (Huguet et al, 1994; Dale et al,
1996; Bui et al, 1997) and/or the loss of Wnt antagonists.
Several classes of secreted Wnt antagonists are known, including
the Cerberus, Wnt inhibitory factor 1, secreted frizzled-related
protein (SFRP) and the Dickkopf (DKK) families (Kawano and
Kypta, 2003). The SFRP family is comprised of five secreted
glycoproteins identified as putative inhibitors of the Wnt signalling
pathway (Jones and Jomary, 2002). Secreted frizzled-related
proteins contain an N-terminal domain homologous to the
cysteine-rich domain (CRD) of Fz and a C-terminal domain with
some homology to netrin. This enables SFRPs to downregulate
Wnt signalling by competing with Fz for Wnt binding via its CRD
domain or by binding directly to Fz (Jones and Jomary, 2002).
Vertebrates express four DKK proteins and a unique DKK3-related
protein called Soggy (Niehrs, 2006). Dickkopf-1 binds to low-
density lipoprotein receptor-related protein 5/6 (LRP5/6) and
another transmembrane protein, Kremen, to selectively inhibit the
canonical Wnt pathway by preventing Wnt and Fz from forming a
ternary complex with LRP5/6 (Niehrs, 2006).
Epigenetic silencing of tumour suppressor and tumour-related
genes in association with promoter CpG island hypermethylation
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sis a frequent event that has been seen in virtually every tumour
type (Ting et al, 2006). When we screened for epigenetically
silenced genes in CRC, we found that multiple members of the
SFRP family are concurrently methylated at high frequencies
among cultured CRC cells and primary CRC specimens (Suzuki
et al, 2002). We also found evidence that loss of SFRP function
contributes to the activation of Wnt signalling in CRC cells (Suzuki
et al, 2004). That SFRP1 is located in a chromosomal region that is
frequently deleted in breast cancer (8p12–p11.1) suggests that
SFRP1 may also play a tumour suppressor role during mammary
tumorigenesis (Ugolini et al, 1999, 2001; Armes et al, 2004).
Consistent with that idea, we have previously found that SFRP1 is
methylated in several breast cancer cell lines (Suzuki et al, 2002),
and two other groups recently reported frequent SFRP1 methyla-
tion in both primary and cultured breast cancer cells (Lo et al,
2006; Veeck et al, 2006). To date, epigenetic silencing of SFRP1 has
been identified in a variety of malignancies, including cancers of
the bladder (Stoehr et al, 2004), prostate (Lodygin et al, 2005), lung
(Fukui et al, 2005) and breast, although abnormalities involving
other SFRP family genes are largely unexplored.
We previously showed that SFRP1, SFRP2 and SFRP5 are
frequently inactivated in CRC and gastric cancer (GC) (Suzuki
et al, 2002; Nojima et al, 2007), and that SFRPs suppress
constitutive Wnt signalling when overexpressed in CRC and GC
cells. Similarly, Bafico et al (2004) reported that constitutive Wnt
signalling could be suppressed in breast cancer cells by SFRP1 and
DKK1. DKK1 also has been shown to be a target of methylation-
associated silencing in CRC cells (Aguilera et al, 2006). In the
present study, we attempted to characterise the epigenetic
abnormalities of Wnt antagonist genes in breast cancer and to
determine whether SFRP genes function as tumour suppressors in
the breast.
MATERIALS AND METHODS
Cell lines and tissue specimens
Six breast cancer cell lines (MDA-MB-231, MDA-MB-435S, MDA-
MB-436, MDA-MB-468, MDA-MB-157, MDA-MB-453) were pur-
chased from the American Type Culture Collection (Manassas, VA,
USA), and five (MCF-7, T-47D, SK-BR-3, MDA-MB-361 and ZR-
75-1) were purchased from Dainippon Sumitomo Pharma (Osaka,
Japan). The two CRC cell lines (RKO and DKO2) used were
described previously (Toyota et al, 2003). All of the cell lines were
cultured in the appropriate medium. To analyse restoration of
SFRP gene expression, cells were treated with 2mM 5-aza-20-
deoxycytidine (DAC) (Sigma, St Louis, MO, USA) for 72h,
replacing the drug and medium every 24h. A total of 38 breast
tumour specimens were obtained from Department of Pathology at
Johns Hopkins Medicine (Baltimore, MD, USA). In addition, 78
primary breast tumour specimens from 78 Japanese patients were
obtained from the First Department of Surgery, Sapporo Medical
University. Informed consent was obtained from all patients before
collection of the specimens. Genomic DNA was extracted using the
standard phenol–chloroform procedure. Total RNA was extracted
by using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and then
treated with a DNA-free kit (Ambion, Austin, TX, USA). Total
RNA from normal breast tissue from a healthy individual was
purchased from BioChain (Hayward, CA, USA).
Reverse transcriptase-PCR
Single-stranded cDNA was prepared using SuperScript III reverse
transcriptase (RT) (Invitrogen). The integrity of the cDNA was
confirmed by amplifying glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). PCR was run in a 50-ml volume containing
100ng of cDNA, 1  Ex Taq Buffer (TaKaRa, Otsu, Japan), 0.3mM
dNTP, 0.25mM each primer and 1U of TaKaRa Ex Taq Hot Start
Version (TaKaRa). The PCR protocol entailed 5min at 951C; 35
cycles of 1min at 951C, 1min at 551C and 1min at 721C; and a 7-
min final extension at 721C. Primer sequences for RT-PCR analysis
are listed in Table 1. Real-time RT-PCR was carried out using
SYBR Green sequence detection reagents (Applied Biosystems,
Foster City, CA, USA) in a 50-ml volume containing l00ng of
cDNA, 25ml of SYBR Green PCR Master Mix (Applied Biosystems)
and 0.2mM each primer. The PCR protocol entailed 5min at 951C
and 40 cycles of 30s at 951C and 1min at 601C. Fluorescent signals
were detected using an ABI 7000 Prism 7000 (Applied Biosystems),
and the accumulation of PCR product was measured in real time as
the increase in SYBR green fluorescence. Data were analysed using
ABI Prism 7000 SDS Software (Applied Biosystems). Standard
curves relating initial template copy number to fluorescence and
amplification cycle were generated using the amplified PCR
product as a template, and were used to calculate mRNA copy
number in each sample. Ratios of the intensities of the target genes
and GAPDH signals were used as a relative measure of the
expression level of target genes. Primer sequences for real-time
RT-PCR are listed in Table 1.
Methylation analysis
Bisulphite treatment of genomic DNA was performed as described
previously (Suzuki et al, 2002). Methylation was then analysed
using methylation-specific PCR (MSP) and bisulphite sequencing.
PCR was run in a 25-ml volume containing 50ng bisulphite-treated
DNA, 1  MSP buffer (67mM Tris-HCl (pH 8.8), 16.6mM
(NH4)2SO4, 6.7mM MgCl2 and 10mM 2-mercaptoethanol),
1.25mM dNTP, 0.4mM each primer and 0.5U of JumpStart REDTaq
DNA Polymerase (Sigma). The PCR protocol for MSP entailed
5min at 951C; 35 cycles of 30s at 951C, 30s at 601C and 30s at
721C; and a 7-min final extension at 721C. The PCR protocol for
bisulphite sequencing entailed 5min at 951C; 35 cycles of 1min at
951C, 1min at 601C and 1min at 721C; and a 7-min final extension
at 721C. Amplified bisulphite-sequencing PCR products were
cloned into pCR2.1-TOPO vector (Invitrogen), and 10 clones from
each sample were sequenced. Primer sequences are listed in
Table 1.
Immunofluorescence microscopy
Cells cultured on chamber slides were washed with PBS and fixed
in 4% paraformaldehyde, after which they were incubated with
anti-b-catenin monoclonal antibody (BD Transduction Labora-
tories, San Diego, CA, USA) and stained with anti-mouse IgG
conjugated with Alexa Fluor 488 (Invitrogen). Cells were then
examined using an FV300-IX71 confocal laser scanning micro-
scope (Olympus, Tokyo, Japan).
Colony formation assays
Cells (2 10
6 cells) were transfected with 5mg of one of the
pcDNA3.1/His-SFRP vectors or with empty vector using the Cell
Line Nucleofector kit V (Amaxa, Cologne, Germany) and a
Nucleofector I electroporation device (Amaxa), according to the
manufacture’s instructions. The SFRP vectors were prepared as
described previously (Suzuki et al, 2004), and an empty vector,
pcDNA3.1/HisA (Invitrogen), was used as a control. Cells were
plated on 60-mm culture dishes and selected for 14 days with
0.6mgml
 1 G418, after which colonies were stained with Giemsa
and counted using National Institute of Health IMAGE software.
Flow cytometry
Fluorescence-activated cell sorting (FACS) analysis was carried out
as described previously (Nojima et al, 2007). Briefly, 2 10
6 cells
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vector as described above. Forty-eight hours after transfection,
the cells were harvested, fixed with methanol, rehydrated with
PBS, treated with 2mgml
 1 RNase for 30min at 371C, stained in
propidium iodide solution (50mgml
 1) and analysed using a
FACSCalibur instrument (Becton Dickinson, San Jose, CA, USA).
Small interfering RNA-mediated knockdown of SFRP1
For small interfering RNA (siRNA)-mediated knockdown of
SFRP1, three different oligonucleotide dsRNAs against SFRP1
(siSFRP1) were generated by Dharmacon (Lafayette, CO, USA),
after which a mixture of the three was used for transfection. The
sequences of the siRNA oligonucleotides are listed in Table 1. A
negative control siRNA, siCONTROL, was also purchased from
Dharmacon. Cells (2 10
6 cells) were transfected with 1.5mgo f
siSFRP1 or siCONTROL using the Cell Line Nucleofector kit V
(Amaxa) and a Nucleofector I electroporation device (Amaxa),
according to the manufacturer’s instructions. Total RNA was
extracted 48h after transfection, and SFRP1 expression was
analysed by RT-PCR.
Cell viability assay
Proliferation of siRNA transfectants was analysed by measuring
the uptake of tritium thymidine in 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assays. Transfected cells
were seeded into 96-well plates to a density of 5 10
3 cells per well.
After incubation for 48h, MTT assays were carried out using a Cell
Counting kit-8 (Dojindo, Tokyo, Japan), according to the
manufacturer’s instructions. The colorimetric read-out in this
assay reflects the number of metabolically active mitochondria,
and thus viable cells, in a given well.
Analysis of TCF/LEF-mediated transcription
An expression vector encoding a mutant form of b-catenin,
pcDNA3.1-b-cateninD45, was prepared as described previously
(Suzuki et al, 2004). For the combination analysis of mutant
b-catenin and siSFRP1, MDA-MB-436 cells were cotransfected
with 5mg of pcDNA3.1-b-cateninD45 or empty vector plus 1.5mgo f
siSFRP1 or siCONTROL using the Cell Line Nucleofector kit V
(Amaxa). RNA was prepared 48h after transfection, and RT-PCR
was performed as described above. For TCF/LEF-responsive
Table 1 Sequences for primers and siRNA used in this study
Gene name Sense Antisense Product size (bp)
RT-PCR
SFRP1 50-CCAGCGAGTACGACTACGTGAGCTT-30 50-CTCAGATTTCAACTCGTTGTCACAGG-30 497
SFRP2 50-ATGATGATGACAACGACATAATG-30 50-ATGCGCTTGAACTCTCTCTGC-30 322
SFRP5 50-CAGATGTGCTCCAGTGACTTTG-30 50-AGAAGAAAGGGTAGTAGAGGGAG-30 346
DKK1 50-CTTTCTCCCTCTTGAGTCCTTCTG-30 50-CATAGCGTGACGCATGCAGCGTT-30 404
Wnt1 50-GTCTGATACGCCAAAATCCGG-30 50-CTCGTTGTTGTGAAGGTTCATG-30 404
Wnt2 50-TTGAAACAAGAGTGCAAGTGCC-30 50-ACTTACACCCACACTTGGTCAT-30 379
Wnt2B 50-GGACTGATCTTGTCTACTTTGAC-30 50-TTGAGTTGAGAGGCTTGAATTGG-30 338
Wnt3 50-ATGACAGCCTGGCCATCTTTG-30 50-AGCCCGTGGCACTTGCATTTG-30 349
Wnt3A 50-GGCATCAAGATTGGCATCCAG-30 50-CACTTGAGGTGCATGTGGCTG-30 404
Wnt4 50-ATGCTCTGACAACATCGCCTA-30 50-TGCGGCTTGAACTGTGCGTTG-30 333
Wnt5A 50-TGGAAGTGCAATGTCTTCCAAG-30 50-AGGTGTTATCCACAGTGCTGCA-30 314
Wnt5B 50-GAAGCTGTGCCAATTGTACCA-30 50-ATCCACAAACTCCTTGGCGAA-30 355
Wnt7A 50-GCAAGCATCATCTGTAACAAGA-30 50-TCTCTTTGTCGCAGCCACAGT-30 310
Wnt7B 50-CATCAACGAGTGCCAGTACCA-30 50-CCTCATTGTTATGCAGGTTCAT-30 353
Wnt11 50-GAACTGCTCCTCCATTGAGCT-30 50-CTTACACTTCATTTCCAGAGAG-30 364
AXIN2 50-GCCAACGACAGTGAGATATCCAGT-30 50-TTGAGGACCCTGGACAGGTGATC-30 455
MMP7 50-GAATGTTAAACTCCCGCGTCATAGA-30 50-CAGCGTTCATCCTCATCGAAGTGA-30 379
GAPDH 50-CGGAGTCAACGGATTGGTCGTAT-30 50-AGCCTTCTCCATGGTGGTGAAGAC-30 307
Real time RT-PCR
SFRP1 50-AGATGCTTAAGTGTGACAAGTTCC-30 50-TCAGATTTCAACTCGTTGTCACAG-30 130
AXIN2 50-TCAAGTGCAAACTTTCGCCAACC-30 50-TAGCCAGAACCTATGTGATAAGG-30 151
MMP7 50-TCACTTCGATGAGGATGAACGC-30 50-ATCACTGCATTAGGATCAGAGGA-30 126
GAPDH 50-CTCTGGTAAAGTGGATATTGTTGC-30 50-CCTTGACGGTGCCATGGAATTTG-30 113
Methylation analysis
SFRP1 MSP-U 50-GTTTTGTAGTTTTTGGAGTTAGTGTTGTGT-30 50-CTCAACCTACAATCAAAAACAACACAAACA-30 135
SFRP1 MSP-M 50-TGTAGTTTTCGGAGTTAGTGTCGCGC-30 50-CCTACGATCGAAAACGACGCGAACG-30 126
SFRP2 MSP-U 50-TTTTGGGTTGGAGTTTTTTGGAGTTGTGT-30 50-AACCCACTCTCTTCACTAAATACAACTCA-30 145
SFRP2 MSP-M 50-GGGTCGGAGTTTTTCGGAGTTGCGC-30 50-CCGCTCTCTTCGCTAAATACGACTCG-30 138
SFRP5 MSP-U 50-GTAAGATTTGGTGTTGGGTGGGATGTTT-30 50-AAAACTCCAACCCAAACCTCACCATACA-30 136
SFRP5 MSP-M 50-AAGATTTGGCGTTGGGCGGGACGTTC-30 50-ACTCCAACCCGAACCTCGCCGTACG-30 141
DKK1 MSP-U 50-TTAAGGGGTTGGAATGTTTTGGGTTTGT-30 50-AAACCTAAATCCCCACAAAACCATACCA-30 163
DKK1 MSP-M 50-AGGGGTCGGAATGTTTCGGGTTCGC-30 50-CCTAAATCCCCACGAAACCGTACCG-30 157
SFRP1 bis-seq 50-GTTTTGTTTTTTAAGGGGTGTTGAG-30 50-CCAAAAACCTCCGAAAACAAAAAAC-30 412
SFRP2 bis-seq 50-TAAGAAAATTTTGGTTGTGTTTTAGTAA-30 50-CAACRAACCAAAACCCTACAACAT-30 290
SFRP5 bis-seq 50-TTAAATGTTTAGGGAGGTAGGGAGT-30 50-AATCGCCCAAATAAATAACAACCTAC-30 293
DKK1 bis-seq 50-GCGGGGTGAAGAGTGTTAAAGGTTT-30 50-GTCACTTTACAAACCTAAATCCCCAC-30 277
siRNA
siSFRP1-1 50-UCUCUGUGCCAGCGAGUUUtt-30 50-AAACUCGCUGGCACAGAGAtt-30
siSFRP1-2 50-GCGAGUUUGCACUGAGGAUtt-30 50-AUCCUCAGUGCAAACUCGCtt-30
siSFRP1-3 50-AGGUGAAGAGCCAGUACUUtt-30 50-AAGUACUGGCUCUUCACCUtt-30
MSP¼methylation-specific PCR; RT¼reverse transcriptase; siRNA¼small interfering RNA.
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pGL3-OT (a TCF/LEF-responsive luciferase reporter plasmid) or
pGL3-OF (a negative control plasmid), 100ng of pcDNA3.1-
b-cateninD45 or empty vector, 1ng of pRL-CMV and 100nM of
siSFRP1 or siCONTROL using Lipofectamine 2000 (Invitrogen).
Firefly and Renilla luciferase activities were measured 48h after
transfection using a Dual-Luciferase Reporter Assay System
(Promega, Madison, WI, USA) and a Lumat LB 9507 luminometer
(Berthold Technologies, Bad Wildbad, Germany).
Statistical analysis
Statistical analyses were carried out using SPSS software (version
11.0; SPSS Inc., Chicago, IL, USA). Mann–Whitney’s U-test and
Fisher’s exact test (two-sided) were used to evaluate the association
between methylation of Wnt antagonist genes and clinicopatho-
logical features. Values of Po0.05 were considered significant.
RESULTS
Analysis of Wnt antagonist gene expression in breast
cancer cell lines
We previously reported that three of the five SFRP genes (SFRP1,
SFRP2 and SFRP5) were frequently methylated and silenced in
CRC and GC cells (Suzuki et al, 2002; Nojima et al, 2007). For that
reason, in the present study we initially evaluated the expression
status of SFRP1, SFRP2 and SFRP5 in a panel of breast cancer
cell lines. We found that SFRP1 mRNA was completely absent in
4 of the 11 cell lines tested (MCF-7, MDA-MB-231, T-47D and
SK-BR-3) and was downregulated in one cell line (MDA-MB-453)
(Figure 1A). Treating the cells with the DNA methyltransferase
(DNMT) inhibitor DAC rapidly restored its expression
(Figure 1A).
SFRP2 expression was absent in eight cell lines (MCF-7, MDA-
MB-231, MDA-MB-435S, MDA-MB-468, T-47D, SK-BR-3, MDA-
MB-453 and ZR-75-1) and downregulated in two (MDA-MB-436
and MDA-MB-361) (Figure 1A), while SFRP5 expression was
absent in nine cell lines (MCF-7, MDA-MB-231, MDA-MB-436,
T-47D, SK-BR-3, MDA-MB-157, MDA-MB-361, MDA-MB-453 and
ZR-75-1) and downregulated in two (MDA-MB-435S and MDA-
MB-468) (Figure 1A). 5-Aza-20-deoxycytidine treatment restored
mRNA expression in the majority of the cells in which SFRP2 and/
or SFRP5 were downregulated (Figure 1A).
As DKK1 was recently shown to be epigenetically silenced in
CRC, we also analysed expression of DKK1 in the breast cancer
cells. We found that DKK1 mRNA was significantly downregulated
in two cell lines (T-47D and MDA-MB-453), and the expression
was restored by DAC treatment (Figure 1A). In contrast to cancer
cells, all Wnt antagonist genes were expressed in normal breast
tissue (Figure 1A).
Analysis of Wnt antagonist gene methylation in breast
cancer cell lines
We next used MSP to analyse the methylation status of Wnt
antagonist genes. A CRC cell line (RKO) in which all of the Wnt
antagonist genes were methylated served as a positive control,
while another CRC cell line (DKO2) in which the DNMT1 and
DNMT3B loci were genetically disrupted served as a negative
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Figure 1 Analysis of the expression and methylation of Wnt antagonist genes in breast cancer cell lines. (A) RT-PCR analysis of SFRP1, SFRP2, SFRP5 and
DKK1 expression in the indicated breast cancer cell lines, with and without DAC treatment, and in a normal breast tissue. Expression of GAPDH was
assessed in all samples to ensure the cDNA quality; dH2O indicates no RNA added. (B) MSP analysis of the indicated breast cancer cell lines and normal
breast tissue. A methylated CRC cell line (RKO) and another CRC cell line in which DNMT1 and DNMT3B were genetically disrupted (double knockout;
DKO2), respectively, served as positive and negative controls of methylation. Bands in the ‘M’ lanes are PCR products obtained with methylation-specific
primers; those in the ‘U’ lanes are products obtained with unmethylated-specific primers; dH2O indicates no DNA added.
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scontrol (Figure 1B). We observed SFRP1 methylation in 7 of the
11 (64%) breast cancer cell lines tested (MCF-7, MDA-MB-231,
T-47D, SK-BR-3, MDA-MB-361, MDA-MB-453 and ZR-75-1)
(Figure 1B). Of those, expression of SFRP1 mRNA was down-
regulated in five, as described above. We also detected SFRP1
methylation in two cell lines in which basal expression of the gene
remained intact (MDA-MB-361 and ZR-75-1) (Figure 1A and B).
As both methylated and unmethylated SFRP1 was detected in these
cells, we suggest that the mRNA was likely transcribed from the
unmethylated allele.
SFRP2 methylation was detected in all 11 cell lines (100%), while
SFRP5 methylation was detected in 10 (91%) (Figure 1B). In
general, we observed a good correlation between methylation and
the expression status of SFRP2 and SFRP5, although there were
some exceptions. For example, some methylation of SFRP2 was
detected in MDA-MB-157 cells (Figure 1B), but they showed a
substantial amount of basal mRNA expression (Figure 1A), which
was likely transcribed from the unmethylated allele. Conversely,
SK-BR-3 cells showed no SFRP5 methylation but did not express
any mRNA. Since DAC treatment did not restore SFRP5 expression
in SK-BR-3 cells, a different mechanism may be responsible for its
silencing.
Methylation of DKK1 was detected in three cell lines (T-47D,
MDA-MB-361 and MDA-MB-453) (Figure 1B), although none of
the cells showed complete methylation of DKK1, and MSP revealed
both methylated and unmethylated DNA (Figure 1B). These results
are consistent with the observation that two cell lines showed
significant downregulation of DKK1 expression, but the silencing
was apparently incomplete, as low levels of expression were
detectable with RT-PCR (Figure 1A). In contrast to cancer cell
lines, no methylation of Wnt antagonist genes was detected in
normal breast tissue (Figure 1B).
To analyse the methylation status in more detail, we carried out
bisulphite sequencing in selected cell lines. Sequencing analysis
revealed that the CpG islands of SFRP1, SFRP2 and SFRP5 are
extensively methylated in MCF-7 cells (Figure 2A–C). By contrast,
almost no methylation of SFRP1 was detected in MDA-MB-436
cells (Figure 2A), which is consistent with the MSP results and the
finding that these cells express SFRP1 (Figure 1). We also analysed
SFRP2 in MDA-MB-436 cells, where both methylated and
unmethylated DNA was detected by MSP. Bisulphite sequencing
revealed a heterogeneous pattern of SFRP2 methylation
(Figure 2B), and the incomplete silencing of SFRP2 in this cell
line likely reflects the low-density methylation of the gene. A
SFRP1
MCF-7
MDA-MB-436
Normal breast
MCF-7
MDA-MB-436
Normal breast
SFRP2
MCF-7
MDA-MB-468
Normal breast
SFRP5
–150 –100 –50 0 50 100 150 200 bp
0 50 100 150 200 250 bp
–200 –150 –100 –50 0 bp
Figure 2 Bisulphite-sequencing analysis of SFRP gene methylation. (A) Bisulphite sequencing of SFRP1 in the indicated breast cancer cell lines and normal
breast tissue. Open and filled circles represent unmethylated and methylated CpG sites, respectively. The locations of MSP primer sites are shown by arrows
on the top. The location of each CpG site relative to the transcription start site is shown below. (B, C) Bisulphite sequencing of SFRP2 (B) and SFRP5 (C).
CpG sites are represented as in panel A.
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in MDA-MB-468 cells, where partial methylation was detected with
MSP (Figures 1A and 2C). Normal breast tissue showed little or no
methylation of SFRP1, SFRP2 or SFRP5 (Figure 2A–C).
Analysis of Wnt antagonist gene methylation in primary
breast tumours
Our finding of epigenetic silencing of SFRP genes and DKK1 in
breast cancer cell lines prompted us to determine the extent to
which these Wnt antagonist genes are also aberrantly methylated
in primary breast tumours. We first analysed SFRP methylation in
38 breast tumour specimens and frequently found SFRP methyla-
tion in these tumours (SFRP1, 12 out of 38, 32%; SFRP2, 28 out of
38, 74%; SFRP5, 22 out of 38, 58%). We then examined the 78
specimens from Japanese breast cancer patients and found the
SFRP genes to be methylated at similar frequencies (SFRP1, 31 out
of 78, 40%; SFRP2, 60 out of 78, 77%; SFRP5, 55 out of 78, 71%).
On the other hand, methylation of DKK1 was detected in only 15
(19%) of the 78 tumours. We also obtained samples of adjacent
non-tumourous breast tissue from 20 of the 78 Japanese patients.
In general, methylation of SFRPs and DKK1 was tumour-specific or
tumour-predominant, but weak methylation of SFRP genes was
observed in some non-tumourous breast tissues (representative
results are shown in Figure 3). This may have been caused by field
defects.
The clinicopathological features were available from the
Japanese patients, but there were no significant correlations
between the methylation status of the Wnt antagonist genes and
age, pT status, pN status, pM status, oestrogen receptor status or
HER2 status (Table 2).
SFRPs suppress breast cancer cell growth
To determine whether SFRP genes function as tumour suppressors
in breast cancer, we next analysed Wnt signalling in breast cancer
cells. We first used RT-PCR to test for the expression of Wnt
ligands. We found that all of the cell lines expressed at least 6 of the
11 Wnt ligand genes tested (Figure 4). Subsequent immunofluor-
escence analysis of the intracellular distribution of b-catenin in
seven breast cancer cell lines (MCF-7, MDA-MB-231, MDA-MB-
435S, MDA-MB-436, MDA-MB-468, T-47D and SK-BR-3) revealed
nuclear accumulation of b-catenin in four cell lines (MCF-7, MDA-
MB-231, T-47D and SK-BR-3) in which SFRP1, SFRP2 and SFRP5
were silenced (Supplementary Figure 1). No mutation of APC,
Table 2 Clinicopathological features of breast cancer with or without Wnt antagonist genes methylation
SFRP1 SFRP2 SFRP5 DKK1
n UM P-value U M P-value U M P-value U M P-value
Total 78 47 31 18 60 23 55 63 15
Age (years, mean±s.d.) 53.66±11.01 52.22±11.97 53.56±12.03 52.95±11.24 52.78±8.88 53.22±12.31 52.46±11.43 55.73±10.96
pT category
pTis 1 0 1 0.796 0 1 0.629 0 1 0.860 1 0 0.129
pT1 17 12 5 4 13 6 11 13 4
pT2 41 25 16 11 30 10 31 32 9
p T 3 8 4 41 75 38 0
p T 4 7 5 21 61 67 0
pN category
pN0 35 20 15 0.809 9 26 0.678 7 28 0.125 29 6 0.747
p N 1 2 8 2 08 6 2 2 1 1 1 7 2 17
p N 2 6 24 24 1 5 60
p N 3 3 21 03 2 1 30
pM category
pM0 66 40 26 1.000 17 49 0.325 20 46 0.664 53 13 0.583
p M 1 6 42 06 1 5 60
ER
Negative 15 10 5 0.517 6 9 0.292 6 9 0.128 14 1 0.286
Positive 26 13 13 5 21 4 22 19 7
HER2
Negative 24 15 9 0.353 9 15 0.086 5 19 0.714 19 5 0.714
Positive 18 8 10 2 16 5 13 15 3
Histology
Ductal carcinoma in situ 4 3 12 21 34 0
Invasive ductal carcinoma 63 37 26 11 52 18 45 51 12
Lobular carcinoma in situ 0 0 00 00 00 0
Invasive lobular carcinoma 2 1 1 0 2 1 1 1 1
Others 7 6 1 4 3 3 4 5 2
ER¼oestrogen receptor; HER2¼human epidermal growth factor receptor 2.
Ind 8
SFRP1
SFRP2
SFRP5
6 1 d n I 4 d n II n d 1 2
UMUM
NT
UMUM
NT
UMUM
NT
UMUM
NT
DKK1
Figure 3 Analysis of methylation of Wnt antagonist genes in primary
breast cancers. Shown are representative results of MSP analysis of SFRP1,
SFRP2, SFRP5 and DKK1 in primary breast cancer tissues (T) and adjacent
normal breast tissues from the same patients (N).
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suggesting that loss of SFRP gene function might be responsible for
the observed activation of Wnt signalling. To test that idea, we
carried out colony formation assays with MCF-7, T-47D and SK-
BR-3 cells and found that colony formation was diminished in all
cells transfected with any one of the SFRP genes (Figure 5A and B).
Subsequent FACS analysis confirmed induction of apoptosis in SK-
BR-3 cells, showing ectopic expression of SFRPs (Figure 5C).
To test whether the silencing of SFRP expression provides a
growth advantage to breast cancer cells, we examined the effect
of using siRNA (siSFRP1) to disrupt SFRP1 expression. We
initially used three breast cancer cell lines (MDA-MB-435S, MDA-
MB-436 and MDA-MB-468) to assess the knockdown efficiency of
our siSFRP1, which most effectively disrupted SFRP1 expression in
MDA-MB-436 cells (Figure 5D). Subsequent MTT assays showed
that knocking down SFRP1 expression with siSFRP1 increased cell
viability, as compared to cells transfected with control siRNA
(Figure 5E). Secreted frizzled-related proteins thus appear to
suppress breast cancer cell growth, suggesting that they act as
tumour suppressors in breast cancer.
Depletion of SFRP1 upregulates Wnt signalling in breast
cancer cells
To examine the effect of SFRPs on Wnt signalling in breast cancer,
we used a TCF/LEF-responsive reporter (pGL3-OT) to analyse the
basal TCF/LEF transcriptional activity in seven breast cancer cell
lines (MCF-7, MDA-MB-231, MDA-MB-435S, MDA-MB-436,
MDA-MB-468, T-47D and SK-BR-3). However, none of the cell
lines showed upregulated transcriptional activity (data not shown).
We therefore next used siRNA (siSFRP1) to disrupt SFRP1
expression in a breast cancer cell line (MDA-MB-436) and tested
whether loss of SFRP function leads to upregulated Wnt signalling.
Although transient transfection of siSFRP1 reduced levels of SFRP1
mRNA by approximately 90% (Figure 6A and B), no upregulation
in TCF/LEF transcriptional activity was observed (Figure 6C), and
expression of TCF/LEF target genes was unchanged (Figure 6A, D
and E).
By contrast, transient transfection of a mutant form of b-catenin
(b-cateninD45) induced a 10-fold increase of pGL3-OT reporter
activity (Figure 6C) and upregulated the mRNA expression of
AXIN2 and MMP7, two TCF/LEF target genes (Figure 6A, D and E).
Furthermore, reporter assays and analysis of target gene expres-
sion revealed that the combination of SFRP1 depletion and
b-cateninD45 overexpression acted synergistically to upregulate
TCF/LEF transcription (Figure 6A, C–E).
DISCUSSION
Compelling evidence suggests that activation of Wnt signalling
plays an important role in breast cancer. Immunohistochemical
staining carried out by several groups has demonstrated elevated
levels of nuclear and/or cytoplasmic b-catenin in breast tumours
with significant frequency (Lin et al, 2000; Ryo et al, 2001; Chung
et al, 2004). Lin et al (2000) also showed that nuclear and/or
cytoplasmic staining of b-catenin correlated with elevated cyclin
D1, which is one of the known targets of b-catenin/TCF
transcription. However, mutation of APC, CTNNB1 or AXIN is
rare in breast cancer, and thus the mechanism of Wnt signal
activation in this disease is not fully understood.
On the basis of their expression array analysis of chromosome
8p11–21 genes, Ugolini et al (1999) reported that expression of
SFRP1 mRNA is frequently diminished or lost in breast carcinomas,
and they also found that loss of SFRP1 occurs in more than 80% of
invasive breast carcinomas, although not in the medullary type
(Ugolini et al, 2001). Using immunohistochemical analysis,
Klopocki et al (2004) found that expression of SFRP1 protein was
absent in 46% of invasive breast tumours and in 43% of carcinoma
in situ. In addition, two groups recently reported frequent SFRP1
methylation in primary breast tumours (Lo et al, 2006; Veeck et al,
2006), and Bafico et al (2004) clearly demonstrated a novel autocrine
mechanism leading to constitutive Wnt signalling in breast cancer,
which could be suppressed by SFRP1 and DKK1. Taken together,
these results suggest that loss of SFRP1 function is a key mechanism
by which Wnt signalling is activated in breast cancer.
To date, four SFRP family genes (SFRP1, SFRP2, SFRP4 and
SFRP5) and two DKK family genes (DKK1 and DKK3) have been
identified as targets of epigenetic silencing in human tumours
(Suzuki et al, 2002; Roman-Gomez et al, 2004; Lodygin et al, 2005;
Aguilera et al, 2006; Niehrs, 2006). Among them, we showed that
loss of SFRP1, SFRP2 and SFRP5 contributes to Wnt signal
activation in both CRC and GC. Dickkopf proteins bind with LRP5/
6 and inhibit Wnt signalling by preventing Wnt and Fz from
forming a ternary complex with LRP5/6. However, among the DKK
family, DKK3 is the most divergent, as it neither binds LRP5/6 nor
significantly affects Wnt singling (Niehrs, 2006). We therefore
analysed methylation and expression status of SFRP1, SFRP2,
SFRP5 and DKK1. SFRP1, SFRP2, SFRP5 and DKK1 were
methylated in 64, 100, 91 and 27% of the breast cancer cell lines
tested, respectively. In primary breast tumours, methylation
frequencies of SFRP1, SFRP2, SFRP5 and DKK1 were 40, 77, 71
and 19%, respectively. Although the frequency of SFRP1 methyla-
tion in our samples was somewhat lower than those reported by Lo
et al (2006) and Veeck et al (2006), we also found that a substantial
number of breast tumours harbour SFRP1 methylation. In
addition, we found that SFRP2 and SFRP5 are methylated in both
cultured breast cancer cells and primary breast cancers at quite high
frequencies. In contrast to SFRP genes, however, the frequency of
DKK1 methylation in breast cancer was relatively limited.
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Figure 4 Expression of various Wnt ligands in breast cancer cells. Results
of RT-PCR analysis of Wnt ligand gene expression in the indicated breast
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to ensure the cDNA quality; dH2O indicates no RNA added.
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evaluated the expression status of the Wnt ligands in the cell lines.
We previously found that at least 3 of the 11 Wnt ligands were
expressed CRC cell lines (Suzuki et al, 2004), and even more Wnt
ligands were expressed in breast cancer cell lines. Using
immunofluorescence analysis, we observed b-catenin to be present
in the nuclei of four of seven breast cell lines in which multiple
SFRP genes were methylated and silenced. Ectopic expression of
SFRP in breast cancer cells suppressed colony formation and
induced apoptosis. Conversely, SFRP1 knockdown enhanced
breast cancer cell growth. Thus, loss of Wnt antagonists,
particularly SFRPs, appears to contribute to Wnt signal activation
in breast cancer.
On the other hand, we found that none of the breast cancer cell
lines tested showed upregulated TCF/LEF transcriptional activity,
even when they showed a loss of Wnt antagonist genes and nuclear
accumulation of b-catenin, which is consistent with our earlier
findings in GC cells. Although it is well known that mutation in
APC, CTNNB1 and AXIN is infrequent in GC, we found that the
majority of GC cells showed activation and nuclear accumulation
of b-catenin and methylation of multiple SFRP genes (Nojima et al,
2007). Among those GC cells, only a few cell lines in which APC or
CTNNB1 was mutated showed significant upregulation of TCF/LEF
transcriptional activity (Nojima et al, 2007). It is thus possible that
the TCF/LEF reporter assay used may not be sufficiently sensitive
to detect the weak or moderate activation of canonical Wnt
signalling.
Alternatively, the tumour-suppressive function of Wnt antago-
nists may be independent of the Wnt/b-catenin pathway. To clarify
the functional role of SFRP inactivation in breast cancer, we used
siRNA to disrupt endogenous SFRP1 expression. Because none of
the breast cancer cell lines presented aberrant TCF/LEF transcrip-
tion, we used an expression vector encoding a b-catenin mutant to
boost Wnt signalling. We found that the TCF/LEF transcriptional
activity induced by the mutant b-catenin was synergistically
upregulated when combined with SFRP1 depletion, which is
consistent with the recent observation by Fukui et al (2005). Using
non-small-cell lung carcinoma cells in which SFRP1 was methy-
lated, they showed that when SFRP1 was cotransfected with mutant
b-catenin, SFRP1 could attenuate TCF/LEF activity induced by
exogenous b-catenin. Our results demonstrate the potential of
endogenous SFRP1 to inhibit the Wnt/b-catenin pathway in breast
cancer cells.
In summary, we have shown that epigenetic silencing of multiple
Wnt antagonist genes is a common event in breast cancer. In
particular, we found that SFRP2 and SFRP5 are methylated at even
higher frequencies than SFRP1. Taken together, our findings
indicate that the majority of breast tumours harbour methylation
of at least one Wnt antagonist gene, and support the hypothesis
that epigenetic silencing of Wnt antagonist genes is a major cause
of constitutive Wnt signalling in breast cancer. Our data also
suggest that methylation of a set of multiple Wnt antagonist genes
may represent a useful marker in breast cancer.
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